Neurolymphomatosis: Treatment Response and Progression Monitored by 18F-FDG PET/CT

Pierre Abouhamad, Roger Denays, Vincent Baudrez, Jasmine Nguyen, Thierry Dereme and Jean-Philippe Hermanne

Department of Nuclear Medicine, Rega Institute for Medical Research, Belgium
Department of Neurology, Rega Institute for Medical Research, Belgium
Department of Radiology, Rega Institute for Medical Research, Belgium
Department of Hemato-Oncology, Rega Institute for Medical Research, Belgium

^*Correspondance to: Roger Denays 

 PDF  Full Text Mini Review | Open Access

Abstract:

Neurolymphomatosis (NL)) is the term for infiltration of the peripheral nervous system by neurotropic neoplastic cells in the setting of a known or unknown haematological malignancy. Optimal treatment management of this rare clinical entity remains ill defined. We report the case of a 65-year-old woman with plexiform NL of the right sciatic nerve. Initial complete response to systemic chemotherapy, and later, relapse and progression, were accurately assessed by sequential 18-FDG-PET/CT studies, performed after a few cycles of the initial chemotherapy, and following completion of both initial treatment and salvage therapy.

Keywords:

Neurolymphomatosis; PET/CT; Response assessment

Cite the Article:

Abouhamad P, Denays R, Baudrez V, Nguyen J, Dereme T, Hermanne J-P. Neurolymphomatosis: Treatment Response and Progression Monitored by 18F-FDG PET/CT. Clin Oncol. 2017; 2: 1305.